Diagnostics and therapy of hepatitis;Diagnostik und Therapie der Hepatitis

Internist

Volumn 50, Issue 12, 2009, Pages 1358-1368

  Strassburg, C P ^a   Cornberg, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Interferon; Nucleoside analogues; Nucleotide analogues; Vaccination; Viral hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS E VACCINE; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

DELTA AGENT HEPATITIS; GENOTYPE; GERMANY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HIGH RISK POPULATION; HUMAN; INDIVIDUALIZATION; INFECTION PREVENTION; LABORATORY TEST; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; HEPATITIS; HUMANS; VIRAL VACCINES;

EID: 73649133594     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-009-2464-1     Document Type: Review

References (35)

1. 1. Berg T, Sarrazin C, Herrmann E et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609 (Pubitemid 36258782)
2. 2. Chen CJ, Yang HIs, Su J et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73 (Pubitemid 43042691)
3. Chien RN, Liaw YF (2008) Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 22: 1081-1092
4. 4. Cornberg M, Protzer U, Dollinger MM et al. (2007) Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)lnfection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 45: 525-574 (Pubitemid 47056017)
5. Di Bisceglie AM, Shiffman ML, Everson GT et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429-2441
6. Di Marco V, Marzano A, Lampertico P et al. (2004) Clinical outcome of HBeAg-negative chronic hepatitis B in relation tovirological response to lamivudine. Hepatology 40: 883-891
7. 7. Erhardt A, Knuth R, Sagir A et al. (2003) Socioepidemiological data on hepatitis delta in a German university clinic-increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol 41: 523-526 (Pubitemid 36798996)
8. European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50: 227-242
9. Fiore AE (2004) Hepatitis A transmitted by food. Clin Infect Dis 38: 705-715
10. Hadem J, Wedemeyer H, Manns MP (2004) Hepatitis als Reisekrankheit. Internist (Berl) 45: 655-668
11. 11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807 (Pubitemid 36245756)
12. Hammitt LL, Bulkow L, Hennessy TW et al. (2008) Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 198: 1776-1782
13. Kamar N, Mansuy JM, Cointault O et al. (2008) Hepatitis E virus-related cirrhosis in kidney - and kidney-pancreas-transplant recipients. Am J Transplant 8: 1744-1748
14. 14. Lai CL, Shouval D, Lok AS et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1020 (Pubitemid 43357805)
15. 15. Lau GK, Piratvisuth T, Luo KX et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695 (Pubitemid 41007823)
16. Lednar WM, Lemon SM, Kirkpatrick JW et al. (1985) Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 122: 226-233
17. Lewis HC, Wichmann O, Duizer E (2009) Transmission routes and riskfactors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect 1-22
18. Liaw YF, Gane E, Leung N et al. (2009) 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486-495
19. Liaw YF, Sung JJ, Chow WC et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531
20. 20. Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects and complications. Gut 55: 1350-1359 (Pubitemid 44277369)
21. 21. Marcellin P, Chang TT, Lim SG et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348: 808-816 (Pubitemid 36245757)
22. Marcellin P, Heathcote EJ, Buti M et al. (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455
23. 23. Marcellin P, Lau GK, Bonino F et al. (2004) Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: 1206-1217 (Pubitemid 39296307)
24. Potthoff A, Rifai K, Wedemeyer H et al. (2009) Successful treatment of fulminant hepatitis B during pregnancy. Z Gastroenterol 47: 667-670
25. Rizzetto M (2009) Hepatitis D: thirty years after. J Hepatol 50: 1043-1050
26. 26. Rosenau J, Hooman N, Hadem J et al. (2007) Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 13: 367-373 (Pubitemid 46444465)
27. 27. Shrestha MP, Scott RM, Joshi DM et al. (2007) Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356: 895-903 (Pubitemid 46339908)
28. Strassburg CP (2006) What is the influence of genotype on the success of treatment for chronic hepatitis B? Nat Clin Pract Gastroenterol Hepatol 3: 620-621
29. Strassburg CR Manns MP (2009) Lebertransplantation: Indikationen und Ergebnisse. Internist (Berl) 50: 550-560
30. Ter Borg MJ, Janssen HL (2005) Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 143: 391
31. Van Damme P, Banatvala J, Fay O et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362: 1065-1071
32. 32. Veldt BJ, Chen W, Heathcote EJ et al. (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47: 1856-1862 (Pubitemid 351945553)
33. 33. Victor JC, Monto AS, SurdinaTY et al. (2007) Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357: 1685-1694 (Pubitemid 350005150)
34. Wedemeyer H, Cornberg M, Wiegand J et al. (2006) Treatment of acute hepatitis C-howto explain the differences? Gastroenterology 131: 682-683
35. Wedemeyer H, Yurdaydin C, Dalekos G et al. (2007) 72 week data of the HIDIT-I trial: A multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic delta hepatitis. J Hepatol 46: S4